Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$2.66
>-$0.01(-0.37%)
At close: 4:00 PM EDT
$2.66
>-$0.01(-0.37%)
Day’s Range― - ―
52-Week Range$2.13 - $10.89
Previous CloseN/A
Volume118.08K
Average Volume (3M)112.80K
Market Cap
$39.61M
Enterprise Value$6.82
Total Cash (Recent Filing)$24.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Nov 16, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside482.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.11
Revenue Forecast (FY)$266.67K
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway SupportThe ILAP designation provides structured access to UK regulators, health technology bodies and the NHS. This may improve development coordination, regulatory positioning and eventual patient-access planning for a high-unmet-need indication.
Improved Phase 3 StrategyExposure-response findings and patient-selection insights give CervoMed a more defined development strategy after earlier mixed results. Better dose and biomarker alignment could reduce execution risk in the next pivotal study.
Strengthened Intellectual PropertyLong-duration patent protection can support future commercial exclusivity if clinical efficacy is confirmed. It strengthens the strategic value of neflamapimod and may improve the company’s position in partnerships or licensing discussions.
Bears Say
Minimal Commercial RevenueCervoMed has not reached commercial scale and generates little product revenue, leaving its economics dependent on successful clinical development. Large ongoing losses indicate that profitability remains distant and highly contingent on approval.
Heavy Cash Burn And Funding DependencePersistent operating outflows require continued access to equity, partnerships or other financing before meaningful revenue emerges. This limits financial flexibility and creates dilution or execution risk as the pipeline advances toward Phase 3.
Clinical Efficacy UncertaintyAlthough later analyses support a revised dose and target population, the prior Phase 2b outcome leaves efficacy unproven. A future pivotal trial could still fail, materially weakening the pipeline and the company’s long-term prospects.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $2.13 and its highest was $10.89 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $39.61M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Aug 10, 2026. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.797 by $0.157.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.49.
How many shares outstanding does CervoMed have?
CervoMed has 15,119,096 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.797. Following the earnings report the stock price went down -0.348%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (482.71% Upside)
$15.50 (482.71% Upside)
Blogger Sentiment
Bullish
CRVO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 689.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Company Description
CervoMed
CervoMed, Inc. (CRVO) is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system (CNS) and neurodegenerative diseases. The company’s activities center on research and clinical development of drug candidates (including neflamapimod) intended to address conditions such as dementia-related disorders. As a development-stage biopharma company, it does not provide commercial healthcare services and is primarily engaged in advancing its pipeline through clinical trials and regulatory pathways.
CRVO Stock 12 Month Forecast
Average Price Target
$15.50
▲(482.71% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
33.30% Insiders
2.45% Mutual Funds
7.19% Other Institutional Investors
54.79% Public Companies and
Individual Investors